Please provide your email address to receive an email when new articles are posted on . Phase 1 pharmacokinetics results showed comparability between SB17 and ustekinumab. Phase 3 results of SB17 will ...
This IMULDOSA launch will lay the foundation for Accord BioPharma's immunology franchise, demonstrating the company's commitment to addressing critical needs in immune-mediated inflammatory conditions ...
On Tuesday, May 23, 2023, Janssen and Amgen settled their case regarding Amgen’s proposed biosimilar to Stelara in Delaware district court.[1] Stelara, also known as ustekinumab, is an ...
Sandoz (OTCQX:SDZNY) Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has ...
SEOUL, South Korea--(BUSINESS WIRE)--Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has ...
May 23 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab has settled its lawsuit over Amgen Inc's (AMGN.O), opens new tab proposed biosimilar version of J&J's top-selling treatment Stelara for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback